Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

CanTx

2013 FOUNDED
PRIVATE STATUS
Joint Venture LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Developer of ovarian cancer drug. The company develops drugs which destroys the cancer stem cells.

Website
Ownership Status
Privately Held (backing)
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Primary Office
  • New Haven, CT
  • United States

CanTx Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore CanTx‘s full profile, request access.

Request full access to PitchBook

CanTx Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore CanTx‘s full profile, request access.

Request full access to PitchBook

CanTx Executive Team (3)

Name Title Board
Seat
Contact
Info
David Brown Ph.D Chief Scientific Officer
Andrew Heaton Ph.D Vice President, Drug Discovery
Graham Kelly Ph.D Founder